Loading
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (8 ops.)
Latest filing published 01 Sept 2026 for Crinetics Pharmaceuticals, Inc., €582k. Read the official filing
Filing timeline
BuySaleTobin Schilke
Insider track record
Disclosed buys
0
Disclosed sells
8
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Tobin Schilke: trading record in brief
Tobin Schilke is a declared insider at 2 companies (finance chief); the most frequent names are Revance Therapeutics, Inc. and Crinetics Pharmaceuticals, Inc. In total, 35 filings cover trades dated from 30 June 2021 to 1 September 2026.
The open-market record consists of 8 sales worth €763k, with no purchase. Outside the open market, there are 22 share grants. Since January 2026: no purchases and 1 sale on the market.
The record was last updated on 1 September 2026 with a transaction (€582k) in Crinetics Pharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Tobin Schilke
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations35 total
7,956 shares@ US$85.000.0075% mcap9.6% of flowCommon StockSEC:0001628280-26-059883:0
71,471 shares@ US$85.000.067% mcap86.6% of flowCommon StockSEC:0001628280-26-059883:1
471 shares0Common StockSEC:0001628280-26-058664:0
6,713 shares@ US$39.67100.0% of flowCommon StockSEC:0001628280-26-014772:0
32,000 shares0Common StockSEC:0001628280-26-011728:0
52,000 shares0Common StockSEC:0000950170-25-037200:0
97,999 shares@ US$3.6526.6% of flowCommon StockSEC:0000950170-25-015362:0
6,888 shares0Common StockSEC:0000950170-25-014824:0
1,000 shares@ US$2.18450.2% of flowCommon StockSEC:0001479290-25-000005:0
1,000 shares@ US$2.18450.2% of flowCommon StockSEC:0001479290-24-000103:0
3,822 shares@ US$5.3051.4% of flowCommon StockSEC:0001479290-24-000066:0
17,447 shares0Common StockSEC:0001479290-24-000051:0
96,667 shares0Common StockSEC:0001479290-24-000015:0
434 shares@ US$7.470.2% of flowCommon StockSEC:0001479290-24-000005:0
22,620 shares0Common StockSEC:0001479290-23-000099:0
769 shares@ US$15.6060.8% of flowCommon StockSEC:0001479290-23-000083:0
2,701 shares@ US$30.575.9% of flowCommon StockSEC:0001479290-23-000077:0
42,349 shares0Common StockSEC:0001479290-23-000075:0
3,201 shares@ US$31.707.1% of flowCommon StockSEC:0001479290-23-000056:0
3,201 shares@ US$32.157.2% of flowCommon StockSEC:0001479290-23-000053:0
3,739 shares@ US$30.658.2% of flowCommon StockSEC:0001479290-23-000041:0
42,349 shares0Common StockSEC:0001479290-23-000036:0
3,201 shares@ US$33.507.8% of flowCommon StockSEC:0001479290-23-000031:0
2,085 shares@ US$33.215.0% of flowCommon StockSEC:0001479290-23-000018:0
3,201 shares@ US$34.607.8% of flowCommon StockSEC:0001479290-23-000015:0
25 of 35 declarations
